(Press-News.org) Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.
Nora Heisterkamp, PhD, and colleagues at The Saban Research Institute of Children's Hospital Los Angeles have discovered that by targeting the B-cell activating receptor (BAFF-R), chemotherapy-resistant precursor B acute lymphoblastic leukemia cells (pre-B ALL) can be selectively killed in vivo and in vitro. Results will be published on May 13 in Molecular Cancer Therapeutics.
Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors, called B-cell lymphoblasts, in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80 to 85% of childhood ALL. Although the cure rate has increased, further advances can only be achieved by identifying mechanisms to treat specific subsets of chemotherapy-resistant leukemia cells.
In a previous study (Leukemia, 2013), the researchers had shown that BAFF-R is expressed on pre-B ALL cells but not on their normal counterparts, making selective killing of ALL cells possible by targeting this receptor.
"We've now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said Heisterkamp, who is also professor of Research, Pediatrics and Pathology at the Keck School of Medicine of the University of Southern California.
Using a genetically-engineered antibody (anti-BAFF-R monoclonal antibody), Heisterkamp and colleagues have demonstrated that the BAFF-R could be successfully blocked in a dose-dependent manner. Inhibition of BAFF-R function rendered leukemia cells less viable in mouse models of the disease. Also, the presence of this antibody on the pre-B ALL cells resulted in increased killing of the cancer cells by natural killer (NK) cells and macrophages.
"We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent," said Heisterkamp. "We are looking at a potential one, two punch." Heisterkamp and her colleagues will continue to evaluate the use of this antibody for the treatment of ALL.
INFORMATION:
Co-authors include Reshmi Parameswaran, Min Lim, Fei Fei, Hisham Abdel-Azim, Anna Arutyunyan, Isabelle Schiffer, John Groffen, of The Saban Research Institute of Children's Hospital Los Angeles; and Margaret E. McLaughlin, Hermann Gram, Heather Huet, of Novartis Institute for Biomedical Research.
Funding for this research came from National Institutes of Health grants PHS CA090321, CA 172040, Alex's Lemonade Stand Foundation for Childhood Cancer, the V-Foundation for Cancer Research and Novartis Pharmaceuticals.
About Children's Hospital Los Angeles
Children's Hospital Los Angeles has been named the best children's hospital in California and among the top five in the nation for clinical excellence with its selection to the prestigious US News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States, is one of America's premier teaching hospitals and has been affiliated with the Keck School of Medicine of the University of Southern California since 1932.
For more information, visit http://www.CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog: http://www.WeTreatKidsBetter.org.
Media Contact: Ellin Kavanagh, ekavanagh@chla.usc.edu
(323) 361-8505
Novel target found for chemotherapy-resistant leukemia cells
2014-05-13
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment
2014-05-13
Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer and, in fact, can be detrimental, according to a study by UCLA researchers.
The study followed the cases of more than 140,500 men aged 66 and older diagnosed with early-stage prostate cancer between 1991 and 2007 from the Surveillance, Epidemiology and End Results (SEER) Medicare database. Men who also suffered from multiple major medical conditions such as a history of ...
Study: Former prisoners, parolees turn to emergency departments for care
2014-05-12
AURORA, Colo. (May 12, 2014) – Being released from prison or jail is a difficult time for the millions of Americans returning to their communities from correctional facilities. Add to the list of challenges a high risk of winding up in the emergency department or the hospital. That's according to a new study from the University of Colorado School of Medicine.
The study, published in the Journal of General Internal Medicine, provides support for efforts to improve access to insurance and readily available health care for this vulnerable group.
"This study comes at a ...
Researchers find new molecule to treat asthma
2014-05-12
La Jolla, Calif., May 12, 2014 -- A new study carried out by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Max Planck Institute for Colloids and Interfaces (Germany), the Free University of Berlin (Germany), UC San Diego, and Shinshu University (Japan) has identified a novel molecule that prevents T-cells from orchestrating asthma brought on by allergens. The findings, published on May 12 in Proceedings of the National Academy of Sciences (PNAS), show promise for a new potent therapeutic agent to treat asthma, a chronic disease affecting ...
JAX researchers identify potential therapeutic target for wound-healing and cancer
2014-05-12
A Jackson Laboratory research team led by Professor Lenny Shultz, Ph.D., reports that a protein involved in wound healing and tumor growth could be a potential therapeutic target.
In one of nature's mixed blessings, the mechanisms that work to heal cuts and wounds, rebuilding damaged cells, can also go out of control and cause cancer. But understanding those mechanisms could lead to new ways of stimulating healing in wound patients and dialing back cancerous proliferation.
An inactive rhomboid protease, iRhom2, is normally a short-lived protein that controls a cascade ...
Airborne radar surveys and data-based models indicate West Antarctic Ice Sheet collapse is underway
2014-05-12
National Science Foundation- (NSF) funded researchers at the University of Washington have concluded that Antarctica's fast-moving Thwaites Glacier will likely disappear in a matter of centuries, potentially raising sea level by more than a half-a-meter (two feet).
Data gathered by NSF-funded airborne radar, detailed topography maps and computer modeling was used to make the determination.
The glacier acts as an ice dam, stabilizing and regulating movement toward the sea of the massive West Antarctic Ice Sheet. The ice sheet contains enough ice to cause another 3 to ...
Henry Ford researchers identify genetic factors that may aid survival from brain cancer
2014-05-12
DETROIT – A Henry Ford Hospital research team has identified specific genes that may lead to improved survival of glioblastoma, the most common and deadly form of cancerous brain tumor.
The molecular data is expected to aid further research into genes that either help or impede the survival of patients diagnosed with the tumor, which can invade and rapidly grow in any part of the human brain.
"Studies such as ours that help define molecular alterations associated with short-term survival likely will help define the reasons why our current treatments don't succeed in these ...
Researchers find a new gene expression mechanism of PRRS virus
2014-05-12
MANHATTAN, Kan. — A collaborative study involving Kansas State University researchers has discovered a new gene expression mechanism in porcine reproductive and respiratory syndrome, or PRRS, virus — an important swine pathogen that costs the U.S. pork industry more than $600 million a year. The discovery provides a new avenue for scientists to explore strategies to control and prevent the disease.
Ying Fang, Ph.D., associate professor of diagnostic medicine and pathobiology at Kansas State University, led a study that looked at the unique gene expression mechanism of ...
Hospitals ranked on complications after hip and knee replacement surgeries
2014-05-12
With an aging population comes an increase in hip and knee joint replacement surgeries, totaling almost one million procedures per year in the United States. To provide better information on the outcomes of these surgeries, help inform patient choice, and improve the quality of the nation's hospitals, a team of Yale School of Medicine researchers have developed a measure for hospitals based on the complications following their patients' hip and knee replacements.
The team published an article in the May issue of the Journal of Bone and Joint Surgery showing there are ...
Dartmouth scientists identify genetic blueprint for cancerous tumors of the appendix
2014-05-12
Using next generation DNA sequencing, Dartmouth scientists have identified potentially actionable mutations in cancers of the appendix. Their study, "Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel Sequencing to Identify Somatic Mutations," was published in the journal Clinical Chemistry today. When specific mutations for a cancer type are identified, patients can be treated with chemotherapy or other targeted agents that work on those mutations.
Little is known about the molecular biology of two types of appendix tumors, low-grade appendiceal ...
Ames Lab creates multifunctional nanoparticles for cheaper, cleaner biofuel
2014-05-12
The U.S. Department of Energy's Ames Laboratory has created a faster, cleaner biofuel refining technology that not only combines processes, it uses widely available materials to reduce costs.
Ames Laboratory scientists have developed a nanoparticle that is able to perform two processing functions at once for the production of green diesel, an alternative fuel created from the hydrogenation of oils from renewable feedstocks like algae.
The method is a departure from the established process of producing biodiesel, which is accomplished by reacting fats and oils with alcohols.
"Conventionally, ...